VVUS Key Stats
| Income Statement | |
| Revenue TTM | 2.012M |
| Revenue Quarterly YoY Growth | |
| EPS Diluted TTM | -1.403 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -139.88M |
| Profitability | |
| Gross Profit Margin Quarterly | 90.72% |
| Profit Margin Quarterly | -2875% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 1.325B |
| Enterprise Value | 1.092B |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 5.943 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | -59.43M |
| Return on Equity | -55.03% |
VVUS News
- QVT Financial Purchase $20M of Convertible Debt Issued by VIVUS (VVUS) Street Insider May 20
- The 9 Most Obese Countries in the World Fool May 20
- Vivus Taps Into More Cash May 19
- 25 Belt-Busting Obesity Facts Fool May 18
- VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regula... May 16
- VIVUS (VVUS) Prices $220M Convertible Debt Offering Street Insider May 16
- VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior ... May 16
- Weight Loss Isn't Just for Looking Good Anymore Fool May 15
- Is Vivus a Buy at These Prices? May 15
- VIVUS INC Financials May 15
VVUS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Vivus is down 41.25% over the last year vs S&P 500 Total Return up 31.95%, Arena Pharmaceuticals up 44.84%, and Orexigen Therapeutics up 77.47%.
VVUS Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Cash Flow Statement View Statement
You may also be interested in these VVUS related companies
Pro Ratings for VVUS
Pro Report PDF for VVUS
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download VVUS Pro Report PDF
Pro Strategies Featuring VVUS
Did Vivus make it into our Pro Portfolio Strategies?
VVUS Profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Vivus is a small pharmaceutical company working in obesity, sleep, and sexual health. Vivus is developing an erectile dysfunction drug, Avanafil, that is in Phase 3 clinical trials. A documentary movie "Orgasm Inc." was made at Vivus in 2009 to document the process of creating a treatment for Female sexual arousal disorder. VIVUS, Inc. has a licensing agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Avanafil. The company was founded by Virgil A Place on April 16, 1991 and is headquartered in Mountain View, California.
Other VVUS Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VVUS | 13.16 | +0.18 | +1.39% | 1.325B |
